Our Presenting Sponsor!

Late-stage drug failures cost the industry billions — and most are rooted in toxicology signals that earlier, better models could have caught. VivoSim Labs was built to change that.

Based in San Diego, VivoSim offers NAMkind™ — a proprietary suite of 3D human primary cell-derived liver and intestinal models that outperform traditional 2D, animal-derived, and in vitro systems in predicting human-specific safety responses. Unlike conventional preclinical testing, NAMkind™ models are designed to deliver clarity at three critical decision points: prospective toxicity screening during Hit-to-Lead, translational bridging through Candidate Nomination, and investigative toxicology when unexpected findings demand fast answers.

Each study is bespoke — tailored to the client's compound class, timeline, and budget — and backed by a comprehensive assay portfolio spanning cell viability, barrier integrity, hepatocyte function, gene expression, inflammatory markers, and histological assessment.

Whether you're triaging a compound series, building a regulatory narrative, or troubleshooting a failed animal study, VivoSim gives drug developers the human-relevant data they need to move forward with confidence — or stop before it's too late.